Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $177.00.
A number of equities research analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th.
Read Our Latest Stock Report on Jazz Pharmaceuticals
Insider Transactions at Jazz Pharmaceuticals
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC lifted its position in shares of Jazz Pharmaceuticals by 1,808.4% in the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after purchasing an additional 427,246 shares during the period. Wedge Capital Management L L P NC purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $32,497,000. Pacer Advisors Inc. lifted its holdings in Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares during the period. Point72 Asset Management L.P. boosted its position in Jazz Pharmaceuticals by 20,323.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 182,015 shares of the specialty pharmaceutical company’s stock valued at $19,427,000 after acquiring an additional 182,915 shares in the last quarter. Finally, Cinctive Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $14,277,000. Institutional investors own 89.14% of the company’s stock.
Jazz Pharmaceuticals Stock Performance
Jazz Pharmaceuticals stock opened at $124.39 on Tuesday. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $7.52 billion, a PE ratio of 17.52, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The firm’s 50 day simple moving average is $122.37 and its 200 day simple moving average is $115.45.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Jazz Pharmaceuticals
- How to Use the MarketBeat Excel Dividend Calculator
- Sizing Up a New Opportunity for NVIDIA Investors
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- How to Find Undervalued Stocks
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.